Brainstorm Cell Therapeutics (NASDAQ: BCLI) stock is up 47% premarket. BCLI stock rising is one of those things that a sober reading of the objective evidence would not lead us to expect. Therefore we’ve a number of alternative explanations. Perhaps no one’s sober, or they’re not reading - but a more likely explanation is simpy a bit of speculative activity. This does, as we know, happen often enough in small cap pharma development companies.
As to what happens at Brainstorm: “Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.”
And that’s where the problem lies.

Brainstorm Cell Therapeutics stock price from Google Finance
For the FDA has recently ruled on that ALS treatment: “The US FDA’s Cellular, Tissue and Gene Therapies Advisory Committee has reviewed and rejected a Biologics License Application for an investigational mesenchymal stem cell therapy developed by BrainStorm Cell Therapuetics Inc. (NY, USA). The Committee decided that the Phase III results of NurOwn, which is designed to treat ALS, failed to provide substantial therapeutic evidence of effectiveness for mild and moderate forms of the condition.”
Which is also known as the FDA insisting that it doesn’t work. Or at least, doesn’t work well enough to be licenced. “The FDA, in its briefing documents, said it does not believe there is sufficient evidence to support NurOwn's clinical benefit, adding there were large amounts of missing data. The health regulator also identified a higher incidence of deaths in the treatment group and said it indicates a lack of survival benefit and warrants further investigation.”
At this stage this is something that can be appealed, worked upon. But that hope’s worth a near 50% rise in the price today? Hmm, no, we think this is a speculative flurry which is likely to fade. For any FDA reconsideration is going to take months, if not years.



